M. Schmitz

Linda J. C. van Waalwijk van Doorn, K. Jellinger, A. Fagan, 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid

K. Blennow, A. Sartorius, M. Schwarz, 2019, European Archives of Psychiatry and Clinical Neuroscience.

Synthesis, structural characterization and study of antioxidant and anti-PrPSc properties of flavonoids and their rhenium(I)–tricarbonyl complexes

I. Zerr, D. Hadjipavlou-Litina, T. Sklaviadis, 2023, JBIC Journal of Biological Inorganic Chemistry.

Plasma YKL-40 in the spectrum of neurodegenerative dementia

D. Varges, I. Zerr, F. Llorens, 2019, Journal of Neuroinflammation.

TREM2 expression in the brain and biological fluids in prion diseases

K. Blennow, B. Mollenhauer, J. D. del Río, 2021, Acta Neuropathologica.

YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias

I. Ferrer, I. Zerr, R. Sánchez-Valle, 2017, Molecular Neurodegeneration.

Molecular Alterations in the Cerebellum of Sporadic Creutzfeldt–Jakob Disease Subtypes with DJ-1 as a Key Regulator of Oxidative Stress

B. Mollenhauer, I. Zerr, F. Llorens, 2016, Molecular Neurobiology.

BAG1 Overexpression Stabilizes High Molecular Tau Protein – a Crucial Role of the Co-chaperone in Tau Pathology

F. Wouters, P. Kermer, M. Schmitz, 2021, American Journal of Psychiatry and Neuroscience.

Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia

I. Zerr, F. Llorens, A. Fischer, 2017, Front. Aging Neurosci..

Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases

B. Mollenhauer, P. Liberski, D. Varges, 2017, Alzheimer's & Dementia.

Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease

A. Karch, B. Mollenhauer, P. Liberski, 2017, Molecular Neurobiology.

Regulation of human cerebrospinal fluid malate dehydrogenase 1 in sporadic Creutzfeldt-Jakob disease patients

I. Zerr, F. Llorens, I. Ferrer, 2016, Aging.

Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies

B. Mollenhauer, D. Varges, I. Zerr, 2016, Journal of Neurology.

Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia

A. Karch, D. Varges, I. Zerr, 2016, Alzheimer's & Dementia.

Stability and Reproducibility Underscore Utility of RT-QuIC for Diagnosis of Creutzfeldt-Jakob Disease

A. Karch, D. Varges, I. Zerr, 2015, Molecular Neurobiology.

Regional and subtype-dependent miRNA signatures in sporadic Creutzfeldt-Jakob disease are accompanied by alterations in miRNA silencing machinery and biogenesis

J. Díez, J. D. del Río, I. Zerr, 2018, PLoS pathogens.

Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD

B. Mollenhauer, I. Zerr, F. Llorens, 2015, Journal of Neurology.

α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B

I. Zerr, J. Rhee, T. Outeiro, 2017, Nature Neuroscience.

Effect of Cavtratin, a Caveolin-1 Scaffolding Domain Peptide, on Oligodendroglial Signaling Cascades

H. Althaus, I. Zerr, M. Schmitz, 2011, Cellular and Molecular Neurobiology.

Increased alpha-synuclein tear fluid levels in patients with Parkinson’s disease

A. Leha, I. Zerr, M. Bähr, 2020, Scientific Reports.

Biomarkers in Cerebrospinal Fluid

I. Zerr, J. Gawinecka, M. Schmitz, 2017 .

Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer’s disease

I. Zerr, B. Puig, I. Ferrer, 2021, Molecular neurodegeneration.

Carnosic Acid and Carnosol Display Antioxidant and Anti-Prion Properties in In Vitro and Cell-Free Models of Prion Diseases

D. Dafou, T. Sklaviadis, Ioannis Tsamesidis, 2022, Antioxidants.

Prion Protein Interactome: Identifying Novel Targets in Slowly and Rapidly Progressive Forms of Alzheimer's Disease.

I. Zerr, I. Ferrer, N. Younas, 2017, Journal of Alzheimer's disease : JAD.

Altered Ca2+ homeostasis induces Calpain-Cathepsin axis activation in sporadic Creutzfeldt-Jakob disease

P. Liberski, I. Zerr, S. Bonn, 2017, Acta Neuropathologica Communications.

Role of different recombinant PrP substrates in the diagnostic accuracy of the CSF RT-QuIC assay in Creutzfeldt-Jakob disease

I. Zerr, André Fischer, M. Schmitz, 2022, Cell and Tissue Research.

Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases

I. Zerr, S. Ventura, F. Llorens, 2018, Molecular Neurobiology.

The Priority position paper: Protecting Europe's food chain from prions

A. Aguzzi, K. Kristensson, J. D. del Río, 2016, Prion.

Spongiform encephalopathy in siblings with no evidence of protease-resistant prion protein or a mutation in the prion protein gene

M. Faist, K. Kallenberg, D. Varges, 2013, Journal of Neurology.

Cerebrospinal Fluid Biomarker-Based Diagnosis of Sporadic Creutzfeldt-Jakob Disease: A Validation Study for Previously Established Cutoffs

A. Karch, P. Liberski, I. Zerr, 2017, Dementia and Geriatric Cognitive Disorders.

Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic

A. Karch, J. Laplanche, I. Zerr, 2016, Molecular Neurobiology.

Application of real-time quaking-induced conversion in Creutzfeldt–Jakob disease surveillance

W. Schulz-Schaeffer, I. Zerr, C. Stadelmann, 2023, Journal of Neurology.

Plasma total prion protein as a potential biomarker for neurodegenerative dementia: diagnostic accuracy in the spectrum of prion diseases

P. Liberski, I. Zerr, F. Llorens, 2020, Neuropathology and Applied Neurobiology.

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease

K. Blennow, S. Lehmann, B. Mollenhauer, 2018, Alzheimer's & dementia.

Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases

K. Blennow, I. Ferrer, A. Karch, 2018, Alzheimer's & Dementia.

Cerebrospinal fluid in Creutzfeldt-Jakob disease.

I. Zerr, F. Llorens, M. Schmitz, 2017, Handbook of clinical neurology.

Immune responses in rapidly progressive dementia: a comparative study of neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer’s disease and multiple sclerosis

I. Zerr, M. Schmitz, K. Stoeck, 2014, Journal of Neuroinflammation.

Doxycycline in early CJD: a double-blinded randomised phase II and observational study

Tim Friede, Walter J Schulz-Schaeffer, T. Friede, 2016, Journal of Neurology, Neurosurgery & Psychiatry.

Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance

W. Schulz-Schaeffer, I. Zerr, M. Glatzel, 2018, Neurology.

Diagnostic Accuracy of Prion Disease Biomarkers in Iatrogenic Creutzfeldt-Jakob Disease

I. Zerr, F. Brett, F. Llorens, 2020, Biomolecules.

Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease

I. Ferrer, A. Karch, P. Liberski, 2019, Journal of Clinical Neuroscience.

Cerebrospinal fluid real‐time quaking‐induced conversion is a robust and reliable test for sporadic creutzfeldt–jakob disease: An international study

P. Cras, I. Zerr, F. Tagliavini, 2016, Annals of neurology.

Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease

K. Blennow, D. Varges, I. Zerr, 2021, Alzheimer's Research & Therapy.

Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases

G. Escaramís, B. Mollenhauer, P. Liberski, 2022, Brain : a journal of neurology.

Optimization of the Real-Time Quaking-Induced Conversion Assay for Prion Disease Diagnosis

I. Zerr, F. Llorens, M. Schmitz, 2020, Frontiers in Bioengineering and Biotechnology.

Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients

I. Zerr, I. Santana, R. Sánchez-Valle, 2019, Biomolecules.

Cerebrospinal fluid non-phosphorylated tau in the differential diagnosis of Creutzfeldt–Jakob disease: a comparative prospective study with 14-3-3

I. Zerr, F. Llorens, I. Lachmann, 2019, Journal of Neurology.

Cerebrospinal Fluid Prion Disease Biomarkers in Pre-clinical and Clinical Naturally Occurring Scrapie

I. Zerr, R. Bolea, J. Badiola, 2018, Molecular Neurobiology.

Applications of the real-time quaking-induced conversion assay in diagnosis, prion strain-typing, drug pre-screening and other amyloidopathies

I. Zerr, F. Llorens, M. Schmitz, 2017, Expert review of molecular diagnostics.

CSF biomarkers in neurodegenerative and vascular dementias

I. Ferrer, I. Zerr, F. Llorens, 2016, Progress in Neurobiology.

Amyloid-β 1-42 levels are modified by apolipoprotein E ε4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer's disease.

U. Heinemann, A. Krasnianski, D. Varges, 2011, Journal of Alzheimer's disease : JAD.

Concordance of cerebrospinal fluid real‐time quaking‐induced conversion across the European Creutzfeldt–Jakob Disease Surveillance Network

S. Hornemann, A. Aguzzi, P. Cras, 2022, European Journal of Neurology.

The cellular prion protein and its derived fragments in human prion diseases and their role as potential biomarkers

I. Zerr, F. Llorens, M. Glatzel, 2019, Expert review of molecular diagnostics.

Cerebrospinal fluid tau levels are a marker for molecular subtype in sporadic Creutzfeldt-Jakob disease

A. Karch, I. Zerr, F. Llorens, 2015, Neurobiology of Aging.

Plasma YKL-40 in the spectrum of neurodegenerative dementia

D. Varges, I. Zerr, F. Llorens, 2019, Journal of Neuroinflammation.

α-Synuclein conformers reveal link to clinical heterogeneity of α-synucleinopathies

I. Zerr, M. Glatzel, J. Matschke, 2023, Translational Neurodegeneration.

Cytosolic Trapping of a Mitochondrial Heat Shock Protein Is an Early Pathological Event in Synucleinopathies.

J. Attems, I. Zerr, S. Rizzoli, 2019, Cell reports.

Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays

H. Vanderstichele, I. Zerr, F. Llorens, 2020, Translational Neurodegeneration.

Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays

H. Vanderstichele, I. Zerr, F. Llorens, 2020, Translational Neurodegeneration.

Seeding variability of different alpha synuclein strains in synucleinopathies

I. Zerr, W. Möbius, F. Llorens, 2019, Annals of neurology.

Desmoplakin as a Potential Candidate for Cerebrospinal Fluid Marker to Rule Out 14-3-3 False Positive Rates in Sporadic Creutzfeldt-Jakob Disease Differential Diagnosis

U. Heinemann, I. Zerr, P. Sánchez-Juan, 2011, Neurodegenerative Diseases.

Stratification by Genetic and Demographic Characteristics Improves Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers in Rapidly Progressive Dementia.

A. Karch, I. Zerr, F. Llorens, 2016, Journal of Alzheimer's disease : JAD.

Creutzfeldt-Jakob Disease Subtype-Specific Regional and Temporal Regulation of ADP Ribosylation Factor-1-Dependent Rho/MLC Pathway at Pre-Clinical Stage

I. Zerr, F. Llorens, I. Ferrer, 2015, Journal of Molecular Neuroscience.

Molecular Profiles of Amyloid-β Proteoforms in Typical and Rapidly Progressive Alzheimer’s Disease

I. Zerr, H. Dihazi, Anna-Maria Siegert, 2021, Molecular neurobiology.

MASP-2 saturation curve in cerebrospinal fluid indicates local synthesis and its equilibrium with soluble and associated forms

I. Zerr, M. Schmitz, A. Dorta-Contreras, 2021 .

Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies

S. Hornemann, A. Aguzzi, I. Zerr, 2021, Science advances.

Cytosolic Trapping of a Mi tochondrial Heat Shock Protein Is an Early Pathological Event in Synucleinopathies Graphical

J. Attems, I. Zerr, S. Rizzoli, 2019 .

Electroconvulsive therapy selectively enhances amyloid β 1–42 in the cerebrospinal fluid of patients with major depression: A prospective pilot study

A. Sartorius, L. Frölich, I. Zerr, 2016, European Neuropsychopharmacology.

Oligodendroglial Cells and Neurotrophins: A Polyphonic Cantata in Major and Minor

H. Althaus, M. Schmitz, S. Klöppner, 2008, Journal of Molecular Neuroscience.

Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases

I. Zerr, S. Ventura, F. Llorens, 2018, Molecular Neurobiology.

Creutzfeldt-Jakob Disease Subtype-Specific Regional and Temporal Regulation of ADP Ribosylation Factor-1-Dependent Rho/MLC Pathway at Pre-Clinical Stage

I. Zerr, F. Llorens, I. Ferrer, 2015, Journal of Molecular Neuroscience.

Altered Ca2+ homeostasis induces Calpain-Cathepsin axis activation in sporadic Creutzfeldt-Jakob disease

P. Liberski, I. Zerr, S. Bonn, 2017, Acta neuropathologica communications.

Baseline CSF/Serum-Ratio of Apolipoprotein E and Rate of Differential Decline in Alzheimer's Disease.

T. Friede, I. Zerr, M. Schmitz, 2015, Journal of Alzheimer's disease : JAD.

Plasma Lipocalin 2 in Alzheimer’s disease: potential utility in the differential diagnosis and relationship with other biomarkers

D. Varges, I. Zerr, I. Santana, 2022, Alzheimer's research & therapy.

Increased albumin CSF/serum ratio in dementia with Lewy bodies

D. Varges, I. Zerr, F. Llorens, 2015, Journal of the Neurological Sciences.

Detection of Prion Protein Seeding Activity in Tear Fluids.

I. Zerr, P. Lingor, M. Schmitz, 2023, The New England journal of medicine.

CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD

P. Lewczuk, J. Kornhuber, I. Zerr, 2018, Annals of clinical and translational neurology.

Anchorless 23–230 PrPC Interactomics for Elucidation of PrPC Protective Role

I. Zerr, M. Schmitz, Saima Zafar, 2014, Molecular Neurobiology.

Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases

A. Karch, I. Zerr, I. Santana, 2018, Molecular Neurobiology.

Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt–Jakob Disease and Synucleinopathy

J. Trojanowski, V. Lee, H. Vanderstichele, 2018, Molecular Neurobiology.

Negative Impact of Statins on Oligodendrocytes and Myelin Formation In Vitro and In Vivo

H. Althaus, W. Brück, D. Merkler, 2008, The Journal of Neuroscience.

Impact of the cellular prion protein on amyloid-β and 3PO-tau processing.

F. Wouters, W. Schulz-Schaeffer, I. Zerr, 2013, Journal of Alzheimer's disease : JAD.

Ligands binding to the cellular prion protein induce its protective proteolytic release with therapeutic potential in neurodegenerative proteinopathies

S. Hornemann, A. Aguzzi, I. Zerr, 2021, bioRxiv.

Cytokine profiles and the role of cellular prion protein in patients with vascular dementia and vascular encephalopathy

I. Zerr, F. Llorens, M. Schmitz, 2015, Neurobiology of Aging.

Validation of Poly(Propylene Imine) Glycodendrimers Towards Their Anti-prion Conversion Efficiency

I. Zerr, D. Dafou, T. Sklaviadis, 2019, Molecular Neurobiology.

Cerebrospinal Fluid Prion Disease Biomarkers in Pre-clinical and Clinical Naturally Occurring Scrapie

I. Zerr, R. Bolea, J. Badiola, 2018, Molecular Neurobiology.

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia

K. Blennow, I. Ferrer, O. Hansson, 2020, Nature Communications.

Loss of Prion Protein Leads to Age-Dependent Behavioral Abnormalities and Changes in Cytoskeletal Protein Expression

Christopher J. Silva, W. Schulz-Schaeffer, I. Zerr, 2014, Molecular Neurobiology.

Oligodendroglial Process Formation is Differentially Affected by Modulating the Intra- and Extracellular Cholesterol Content

H. Althaus, I. Zerr, M. Schmitz, 2012, Journal of Molecular Neuroscience.

Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study

K. Blennow, A. Sartorius, M. Schwarz, 2018, Neuropsychobiology.

Haploinsufficiency of the Myc regulator Mtbp extends survival and delays tumor development in aging mice

Hayes, Grogan, Stricker, 2016, Aging.

CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD

P. Lewczuk, I. Zerr, F. Llorens, 2018 .

Impact of the cellular prion protein on amyloid-β and 3PO-tau processing.

F. Wouters, W. Schulz-Schaeffer, I. Zerr, 2013, Journal of Alzheimer's disease : JAD.

Association of prion protein genotype and scrapie prion protein type with cellular prion protein charge isoform profiles in cerebrospinal fluid of humans with sporadic or familial prion diseases

I. Zerr, M. Schmitz, Saima Zafar, 2014, Neurobiology of Aging.

Codon 129 polymorphism and the E200K mutation do not affect the cellular prion protein isoform composition in the cerebrospinal fluid from patients with Creutzfeldt–Jakob disease

D. Varges, I. Zerr, M. Beekes, 2010, The European journal of neuroscience.

Loss of Prion Protein Leads to Age-Dependent Behavioral Abnormalities and Changes in Cytoskeletal Protein Expression

Christopher J. Silva, W. Schulz-Schaeffer, I. Zerr, 2014, Molecular Neurobiology.

Cerebrospinal fluid in Creutzfeldt-Jakob disease.

I. Zerr, F. Llorens, M. Schmitz, 2017, Handbook of clinical neurology.

Genetic Variants Associated with the Age of Onset Identified by Whole-Exome Sequencing in Fatal Familial Insomnia

I. Zerr, N. Younas, M. Schmitz, 2023, Cells.

Cellular prion protein overexpression disturbs cellular homeostasis in SH-SY5Y neuroblastoma cells but does not alter p53 expression: a proteomic study

I. Zerr, B. Ciesielczyk, W. Schulz-Schaeffer, 2010, Neuroscience.

Current Technologies Unraveling the Significance of Post-Translational Modifications (PTMs) as Crucial Players in Neurodegeneration

M. Schmitz, Saima Zafar, Inga Zerr, 2024, Biomolecules.

α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B

I. Zerr, J. Rhee, T. Outeiro, 2017, Nature Neuroscience.

Differential interactome mapping of aggregation prone/prion-like proteins under stress: novel links to stress granule biology

N. Younas, M. Schmitz, Saima Zafar, 2023, Cell & Bioscience.

Cleavage site-directed antibodies reveal the prion protein in humans is shed by ADAM10 at Y226 and associates with misfolded protein deposits in neurodegenerative diseases

R. Nonno, C. Haigh, M. Damme, 2023, bioRxiv.

Cytoskeleton-Associated Risk Modifiers Involved in Early and Rapid Progression of Sporadic Creutzfeldt-Jakob Disease

I. Zerr, I. Ferrer, O. Andréoletti, 2017, Molecular Neurobiology.

A Comparison of RML Prion Inactivation Efficiency by Heterogeneous and Homogeneous Photocatalysis

M. Schmitz, K. Xanthopoulos, I. Paspaltsis, 2024, Pathogens.

Αnti-prion effects of anthocyanins

M. Schmitz, K. Xanthopoulos, Susana Margarida da Silva Correia, 2024, Redox biology.

Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia

I. Zerr, F. Llorens, A. Fischer, 2017, Front. Aging Neurosci..

Application of capillary immunoelectrophoresis revealed an age‐ and gender‐dependent regulated expression of PrPC in liver

I. Zerr, F. Llorens, Prateek Kumar, 2015, Electrophoresis.